Treatment of Pulmonary Embolism in ESRD Patients on Hemodialysis
Initial Anticoagulation Strategy
- In patients with End-Stage Renal Disease (ESRD) on hemodialysis who develop pulmonary embolism (PE), unfractionated heparin (UFH) is the recommended initial anticoagulant due to its predictable clearance and ability to be monitored in renal dysfunction, as recommended by the European Society of Cardiology 1, 2
- Immediate intravenous UFH should be initiated without delay with an 80 U/kg bolus followed by 18 U/kg/h continuous infusion in high-risk PE patients with hemodynamic instability, as suggested by the European Heart Journal 2, 3
- Target aPTT should be 1.5-2.5 times normal (corresponding to anti-Xa activity of 0.3-0.6 IU) in patients with ESRD on hemodialysis, according to the European Heart Journal 4, 5
- Thrombolytic therapy should be considered in patients with cardiogenic shock and/or persistent arterial hypotension, as recommended by the European Heart Journal 1, 2
- Surgical pulmonary embolectomy may be considered when thrombolysis is contraindicated or has failed, as suggested by the European Heart Journal 2, 7
UFH Dosing Adjustment Protocol
- The following protocol should be used to adjust UFH dosing:
| aPTT | Adjustment |
|---|---|
| <35 s (<1.2× normal) | 80 U/kg bolus; increase rate by 4 U/kg/h |
| 35-45 s (1.2-1.5× normal) | 40 U/kg bolus; increase rate by 2 U/kg/h |
| 46-70 s (1.5-2.3× normal) | No change |
| 71-90 s (2.3-3.0× normal) | Decrease rate by 2 U/kg/h |
| >90 s (>3.0× normal) | Stop infusion for 1 h, then decrease rate by 3 U/kg/h |
Long-Term Anticoagulation
- Vitamin K antagonists (VKAs) are the preferred long-term anticoagulant for ESRD patients on hemodialysis, as recommended by the European Society of Cardiology 1, 2
- Target INR should be 2.0-3.0 (target 2.5) in patients with ESRD on hemodialysis, according to the European Heart Journal 1, 2
- Duration of anticoagulation depends on whether PE was provoked or unprovoked, with a minimum of 3-6 months, as suggested by the European Heart Journal 1
Special Considerations in ESRD Patients
- Direct oral anticoagulants (DOACs) are generally not recommended in ESRD patients due to limited data and concerns about drug accumulation, as recommended by the Thorax journal 8, 9
- Regular monitoring of anti-Xa levels may be necessary in cases where aPTT is unreliable, according to the European Heart Journal 4, 5
Monitoring and Follow-up
- Frequent aPTT monitoring is essential during UFH therapy to maintain therapeutic anticoagulation, as recommended by the European Heart Journal 4, 5
- Platelet count should be monitored to detect heparin-induced thrombocytopenia, as suggested by the Thorax journal 9
- When transitioning to VKAs, overlap with UFH for at least 5 days and until INR is therapeutic for 2 consecutive days, as recommended by the European Heart Journal 1, 2
- Regular assessment of bleeding risk throughout treatment is crucial, according to the European Heart Journal 2
Pitfalls and Caveats
- Avoid LMWH for initial treatment of PE in ESRD patients due to unpredictable pharmacokinetics and bioaccumulation, as recommended by the European Heart Journal 1, 2
- Avoid aggressive fluid challenges in PE patients with right ventricular dysfunction, as suggested by the European Heart Journal 1, 2
- Be cautious with thrombolysis in ESRD patients due to increased bleeding risk; reserve for high-risk PE with hemodynamic compromise, as recommended by the European Heart Journal 1, 2